Details

Autor(en) / Beteiligte

• Aubier, M
• Lode, H
• Gialdroni-Grassi, G
• Huchon, G
• Hosie, J
• Legakis, N
• Regamey, C
• Segev, S
• Vester, R
• Wijnands, W J
• Tolstuchow, N
• White, LO (eds)
• Bint, AJ
• Hunter, PA
• Finch, RG

Titel

Sparfloxacin for the treatment of community-acquired pneumonia: A pooled data analysis of two studies

Ist Teil von

• Journal of Antimicrobial Chemotherapy [J. ANTIMICROB. CHEMOTHER.]. Vol. 37, no. A Suppl. May 1996, 1996, Vol.37, p.no. A Sul.-no. A Sul.

Erscheinungsjahr

1996

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• A pooled data analysis of two double-blind studies encompassing 1137 episodes of community-acquired pneumonia in hospitalised adults, of which 560 were treated with sparfloxacin and 577 were randomised to comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin administered at reference dosages), was performed. The global efficacy rate at the end of treatment in evaluable patients treated with sparfloxacin was 88.3% compared with 84.1% in those who received comparator antibacterial agents. This analysis verified the efficacy of this new aminofluoroquinolone, given orally once daily, in the treatment of community acquired pneumonia. The overall outcome favoured sparfloxacin for use in the empirical treatment of community-acquired pneumonia.